FDA+ roundup: Agency reopens AI discussion paper for comments amid two-day workshop
The FDA is reopening the comment period on its discussion paper on using artificial intelligence in drug development, coinciding with a two-day workshop on the topic.
The agency in March published a discussion paper on the use of AI in drug development, which laid out considerations and potential areas for policy development in that area. The original comment period ended on May 1, but the FDA on Tuesday reopened it for another 60 days to allow for more comments following its two-day workshop on the topic being held Tuesday and Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.